EUVIMEDEUVIMED entdecken
Crossref

"The Century of Biology": The Making of China's Biopharmaceutical Industry, 1976-2026

Andrew Kelmanson, Jean C. Oi, Mikael D. Wolfe

Stanford Digital Repository · 22.06.2026

DOI: 10.25740/qd419ny2116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stanford Digital Repository, erschienen am 22.06.2026. Verfasst von Andrew Kelmanson und 2 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This thesis investigates how China’s biopharmaceutical ascent occurred over the course of a five-decade period (1976-2026) from the end of the Cultural Revolution to the Present. It argues that the rise of China’s biopharmaceutical sector cannot be explained solely by national level policies, most often credited as the primary factor by existing literature and Western policy reports; rather, conditions such as homegrown Chinese CROs and CDMOs, Western MNCs’ establishing offices in Mainland China, city-state government policymaking, and large waves of returnees arriving at the right time with the right knowledge in a sufficiently developed enough biopharma ecosystem created the conditions for national policies to succeed, not the other way around. Thus, this thesis challenges prevailing narratives in existing literature, such as the idea that China’s biotech industry has been built solely by factors such as efficient, sweeping national-level government policies in the late 2010s like the 2015 NMPA or 2018-2019 capital market reforms, that the mere return of scientists created the biopharma industry without proving causation, that 2000-2015 represented a desert in the development of China’s biopharma industry, or that the Chinese government acts as a solely top-down actor devolving commands to city-state governments who then acted passively rather than actively. Methodologically, this research draws on a variety of original primary and secondary sources and accompanying analysis: an original scraped dataset of 222 executive biographies from nearly all of China’s leading innovative biopharma firms, personal accounts from interviews with 16 China-based biopharma executives, including leaders of publicly-listed companies and a state-investment director, dozens of primary and secondary source documents spanning 40 years, data on the development of MNCs in China, data on China’s innovative public and private biopharma companies, and personal experiences working in healthcare investment banking on Wall Street researching China’s biopharmaceutical companies.

Schlagwörter

biopharmaceutical industryChinaregulatory policyNational Medical Products Administrationmultinational corporationscontract research organizationscontract development and manufacturing organizationsreturneesexecutive biographypublic investment

Zitieren

APA

Kelmanson, A., Oi, J. C., & Wolfe, M. D. (2026). "The Century of Biology": The Making of China's Biopharmaceutical Industry, 1976-2026. Stanford Digital Repository. https://doi.org/10.25740/qd419ny2116

Vancouver

Kelmanson A, Oi JC, Wolfe MD. "The Century of Biology": The Making of China's Biopharmaceutical Industry, 1976-2026. Stanford Digital Repository. 2026. doi:10.25740/qd419ny2116

BibTeX
@article{Kelmanson2026,
  author = {Kelmanson, Andrew and Oi, Jean C. and Wolfe, Mikael D.},
  title = {"The Century of Biology": The Making of China's Biopharmaceutical Industry, 1976-2026},
  journal = {Stanford Digital Repository},
  year = {2026},
  doi = {10.25740/qd419ny2116}
}
Kostenlos starten →